Insights into molecular classifications of triple-negative breast cancer: improving patient selection for treatment
AC Garrido-Castro, NU Lin, K Polyak - Cancer discovery, 2019 - AACR
Triple-negative breast cancer (TNBC) remains the most challenging breast cancer subtype
to treat. To date, therapies directed to specific molecular targets have rarely achieved …
to treat. To date, therapies directed to specific molecular targets have rarely achieved …
Targeted therapies for triple-negative breast cancer
TG Lyons - Current treatment options in oncology, 2019 - Springer
Opinion statement Triple-negative breast cancer (TNBC) is a particularly aggressive subtype
of breast cancer. TNBC is a heterogenous subtype of breast cancer that is beginning to be …
of breast cancer. TNBC is a heterogenous subtype of breast cancer that is beginning to be …
Long-term clinical outcomes and biomarker analyses of atezolizumab therapy for patients with metastatic triple-negative breast cancer: a phase 1 study
Importance Atezolizumab (anti–programmed cell death ligand 1 [PD-L1]) is well tolerated
and clinically active in multiple cancer types. Its safety and clinical activity in metastatic triple …
and clinically active in multiple cancer types. Its safety and clinical activity in metastatic triple …
Single-cell profiling of breast cancer T cells reveals a tissue-resident memory subset associated with improved prognosis
The quantity of tumor-infiltrating lymphocytes (TILs) in breast cancer (BC) is a robust
prognostic factor for improved patient survival, particularly in triple-negative and HER2 …
prognostic factor for improved patient survival, particularly in triple-negative and HER2 …
Immunotherapy and targeted therapy combinations in metastatic breast cancer
Immunotherapy is emerging as a new treatment modality in breast cancer. After long-
standing use of endocrine therapy and targeted biological therapy, improved understanding …
standing use of endocrine therapy and targeted biological therapy, improved understanding …
[HTML][HTML] Prevalence and mutational determinants of high tumor mutation burden in breast cancer
Background High tumor mutation burden (TMB) can benefit immunotherapy for multiple
tumor types, but the prevalence of hypermutated breast cancer is not well described. The …
tumor types, but the prevalence of hypermutated breast cancer is not well described. The …
[HTML][HTML] Eradication of triple-negative breast cancer cells by targeting glycosylated PD-L1
Protein glycosylation provides proteomic diversity in regulating protein localization, stability,
and activity; it remains largely unknown whether the sugar moiety contributes to …
and activity; it remains largely unknown whether the sugar moiety contributes to …
Breast cancers are immunogenic: immunologic analyses and a phase II pilot clinical trial using mutation-reactive autologous lymphocytes
PURPOSE Metastatic breast cancer (mBrCa) is most often an incurable disease with only
modest responses to available immunotherapies. This study investigates the …
modest responses to available immunotherapies. This study investigates the …
[HTML][HTML] Triple-negative breast cancer: recent treatment advances
ART Bergin, S Loi - F1000Research, 2019 - ncbi.nlm.nih.gov
Triple-negative breast cancer (TNBC) is a breast cancer subtype renowned for its capacity to
affect younger women, metastasise early despite optimal adjuvant treatment and carry a …
affect younger women, metastasise early despite optimal adjuvant treatment and carry a …
[HTML][HTML] Immunological differences between primary and metastatic breast cancer
B Szekely, V Bossuyt, X Li, VB Wali, GA Patwardhan… - Annals of …, 2018 - Elsevier
Background Little is known about how the immune microenvironment of breast cancer
evolves during disease progression. Patients and methods We compared tumor infiltrating …
evolves during disease progression. Patients and methods We compared tumor infiltrating …